Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00063141




Registration number
NCT00063141
Ethics application status
Date submitted
20/06/2003
Date registered
25/06/2003
Date last updated
12/04/2010

Titles & IDs
Public title
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
Scientific title
Revised Protocol 07 to Protocol CA225006 - A Phase III Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Carcinoma
Secondary ID [1] 0 0
CA225-006
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Colorectal Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - cetuximab
Treatment: Drugs - Irinotecan
Treatment: Drugs - Irinotecan

Experimental: Arm A -

Active comparator: Arm B -


Treatment: Drugs: cetuximab
Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision

Treatment: Drugs: Irinotecan
Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision

Treatment: Drugs: Irinotecan
Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
Every 3 months after subject off-treatment
Secondary outcome [1] 0 0
Progression Free Survival
Timepoint [1] 0 0
Q6 Weeks
Secondary outcome [2] 0 0
Response
Timepoint [2] 0 0
Q6 Weeks
Secondary outcome [3] 0 0
Duration of Response
Timepoint [3] 0 0
Q6 Weeks
Secondary outcome [4] 0 0
Time to Response
Timepoint [4] 0 0
Q6 Weeks
Secondary outcome [5] 0 0
Disease Control Rate
Timepoint [5] 0 0
Q6 Weeks
Secondary outcome [6] 0 0
Safety
Timepoint [6] 0 0
Q3 Weeks
Secondary outcome [7] 0 0
Quality of Life
Timepoint [7] 0 0
Q6 Weeks
Secondary outcome [8] 0 0
Health Economics
Timepoint [8] 0 0
Q3 Weeks

Eligibility
Key inclusion criteria
* Histologically documented colorectal cancer which is EGFR-positive by immunohistochemistry [IHC] (may be based on archival samples) and is metastatic.
* Prior oxaliplatin administered for the first-line treatment of metastatic colorectal cancer.
* Prior fluoropyrimidine-containing regimen (5-fluorouracil [5-FU], capecitabine, or uracil/tegafur [UFT]), for the first-line treatment of metastatic disease.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* A serious uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive protocol therapy
* Unresolved diarrhea, bowel obstruction, or history of inflammatory bowel disease
* Known or documented brain metastases

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2003
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2007
Sample size
Target
Accrual to date
Final
1302
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA
Recruitment hospital [1] 0 0
ImClone Investigational Site - Perth
Recruitment hospital [2] 0 0
ImClone Investigational Site - Sydney
Recruitment hospital [3] 0 0
ImClone Investigational Site - Wollongong
Recruitment hospital [4] 0 0
ImClone Investigational Site - South Brisbane
Recruitment hospital [5] 0 0
ImClone Investigational Site - Adelaide
Recruitment hospital [6] 0 0
ImClone Investigational Site - Wien
Recruitment postcode(s) [1] 0 0
- Perth
Recruitment postcode(s) [2] 0 0
- Sydney
Recruitment postcode(s) [3] 0 0
- Wollongong
Recruitment postcode(s) [4] 0 0
- South Brisbane
Recruitment postcode(s) [5] 0 0
- Adelaide
Recruitment postcode(s) [6] 0 0
- Wien
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Hawaii
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Kansas
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Michigan
Country [17] 0 0
United States of America
State/province [17] 0 0
Minnesota
Country [18] 0 0
United States of America
State/province [18] 0 0
Mississippi
Country [19] 0 0
United States of America
State/province [19] 0 0
Missouri
Country [20] 0 0
United States of America
State/province [20] 0 0
New Jersey
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
North Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
North Dakota
Country [24] 0 0
United States of America
State/province [24] 0 0
Ohio
Country [25] 0 0
United States of America
State/province [25] 0 0
Oklahoma
Country [26] 0 0
United States of America
State/province [26] 0 0
Pennsylvania
Country [27] 0 0
United States of America
State/province [27] 0 0
South Carolina
Country [28] 0 0
United States of America
State/province [28] 0 0
Tennessee
Country [29] 0 0
United States of America
State/province [29] 0 0
Texas
Country [30] 0 0
United States of America
State/province [30] 0 0
Utah
Country [31] 0 0
United States of America
State/province [31] 0 0
Virginia
Country [32] 0 0
United States of America
State/province [32] 0 0
Washington
Country [33] 0 0
United States of America
State/province [33] 0 0
Wisconsin
Country [34] 0 0
Austria
State/province [34] 0 0
Graz
Country [35] 0 0
Austria
State/province [35] 0 0
Salzburg
Country [36] 0 0
Austria
State/province [36] 0 0
Wein
Country [37] 0 0
Austria
State/province [37] 0 0
Wien
Country [38] 0 0
Belgium
State/province [38] 0 0
Charleroi
Country [39] 0 0
Czech Republic
State/province [39] 0 0
Brno
Country [40] 0 0
Czech Republic
State/province [40] 0 0
Olomouc
Country [41] 0 0
Czech Republic
State/province [41] 0 0
Praha 5
Country [42] 0 0
Finland
State/province [42] 0 0
Helsinki
Country [43] 0 0
France
State/province [43] 0 0
Avignon
Country [44] 0 0
France
State/province [44] 0 0
Marseille
Country [45] 0 0
France
State/province [45] 0 0
Nice
Country [46] 0 0
France
State/province [46] 0 0
Saint Herblain
Country [47] 0 0
Germany
State/province [47] 0 0
Aschaffenburg
Country [48] 0 0
Germany
State/province [48] 0 0
Augsburg
Country [49] 0 0
Germany
State/province [49] 0 0
Dessau
Country [50] 0 0
Germany
State/province [50] 0 0
Dortmund
Country [51] 0 0
Germany
State/province [51] 0 0
Essen
Country [52] 0 0
Germany
State/province [52] 0 0
Hamburg
Country [53] 0 0
Germany
State/province [53] 0 0
Hanburg
Country [54] 0 0
Germany
State/province [54] 0 0
Kaiserslautern
Country [55] 0 0
Germany
State/province [55] 0 0
Kassel
Country [56] 0 0
Germany
State/province [56] 0 0
Magdeburg
Country [57] 0 0
Germany
State/province [57] 0 0
Mainz
Country [58] 0 0
Germany
State/province [58] 0 0
Mannheim
Country [59] 0 0
Germany
State/province [59] 0 0
Muchnhen
Country [60] 0 0
Germany
State/province [60] 0 0
Munchen
Country [61] 0 0
Germany
State/province [61] 0 0
Regensburg
Country [62] 0 0
Germany
State/province [62] 0 0
Saarbrucken
Country [63] 0 0
Germany
State/province [63] 0 0
Stralsund
Country [64] 0 0
Germany
State/province [64] 0 0
Stuttgart
Country [65] 0 0
Hong Kong
State/province [65] 0 0
Hong Kong
Country [66] 0 0
Italy
State/province [66] 0 0
Milano
Country [67] 0 0
Italy
State/province [67] 0 0
Ancona
Country [68] 0 0
Italy
State/province [68] 0 0
Bergamo
Country [69] 0 0
Italy
State/province [69] 0 0
Candiolo
Country [70] 0 0
Italy
State/province [70] 0 0
Firenze
Country [71] 0 0
Italy
State/province [71] 0 0
Genova
Country [72] 0 0
Italy
State/province [72] 0 0
Livomo
Country [73] 0 0
Italy
State/province [73] 0 0
Modena
Country [74] 0 0
Italy
State/province [74] 0 0
Napoli
Country [75] 0 0
Italy
State/province [75] 0 0
Perugia
Country [76] 0 0
Italy
State/province [76] 0 0
Reggio Emilia
Country [77] 0 0
Italy
State/province [77] 0 0
Roma
Country [78] 0 0
Italy
State/province [78] 0 0
Rome
Country [79] 0 0
Netherlands
State/province [79] 0 0
Apeldorn
Country [80] 0 0
Netherlands
State/province [80] 0 0
Dordrecht
Country [81] 0 0
Norway
State/province [81] 0 0
Oslo
Country [82] 0 0
Portugal
State/province [82] 0 0
Porto
Country [83] 0 0
Slovakia
State/province [83] 0 0
Bratislava
Country [84] 0 0
Sweden
State/province [84] 0 0
Lund
Country [85] 0 0
Sweden
State/province [85] 0 0
Stockholm
Country [86] 0 0
Switzerland
State/province [86] 0 0
Bern
Country [87] 0 0
Switzerland
State/province [87] 0 0
Liestal
Country [88] 0 0
Switzerland
State/province [88] 0 0
Zurich
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Aberdeenshire
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Avon
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Central
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Dorset
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Greater London
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Hampshire
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Surrey

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Eli Lilly and Company
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Bristol-Myers Squibb
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine whether overall survival is prolonged in subjects with metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with cetuximab in combination with irinotecan compared with irinotecan alone as second-line therapy following treatment with a fluoropyrimidine and oxaliplatin based, non-irinotecan-containing regimen.
Trial website
https://clinicaltrials.gov/study/NCT00063141
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
E-mail: ClinicalTrials@ ImClone.com
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00063141